{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T18:52:19Z","timestamp":1776106339572,"version":"3.50.1"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8,15]]},"DOI":"10.2146\/ajhp140564","type":"journal-article","created":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T16:13:21Z","timestamp":1438791201000},"page":"1357-1364","source":"Crossref","is-referenced-by-count":56,"title":["Once-daily aminoglycoside dosing: An update on current literature"],"prefix":"10.1093","volume":"72","author":[{"given":"Matthew S.","family":"Stankowicz","sequence":"first","affiliation":[{"name":"Director of Faculty Development Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jad","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Director of Faculty Development Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel L.","family":"Brown","sequence":"additional","affiliation":[{"name":"Director of Faculty Development Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041008422142600_b1-0721357","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2165\/00019053-199610050-00007","article-title":"The economic impact of once-daily versus conventional administration of gentamicin and tobramycin","volume":"10","author":"Mithani","year":"1996","journal-title":"Pharmacoeconomics"},{"key":"key\n\t\t\t\t2019041008422142600_b2-0721357","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1592\/phco.21.5.443.34490","article-title":"Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs","volume":"21","author":"Streetman","year":"2001","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t2019041008422142600_b3-0721357","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0140-6736(93)90137-6","article-title":"Once versus thrice daily gentamicin in patients with serious infections","volume":"341","author":"Prins","year":"1993","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041008422142600_b4-0721357","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1086\/313692","article-title":"National survey of extended-interval aminoglycoside dosing","volume":"30","author":"Chuck","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041008422142600_b5-0721357","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.4187\/respcare.02980","article-title":"A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs","volume":"59","author":"Prescott","year":"2014","journal-title":"Respir Care"},{"key":"key\n\t\t\t\t2019041008422142600_b6-0721357","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0891-5520(05)70259-2","article-title":"Once-daily dosing of aminoglycoside antibiotics","volume":"14","author":"Fisman","year":"2000","journal-title":"Infect Dis Clin North Am"},{"key":"key\n\t\t\t\t2019041008422142600_b7-0721357","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis"},{"issue":"suppl A","key":"key\n\t\t\t\t2019041008422142600_b8-0721357","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/15.suppl_A.37","article-title":"Postantibiotic effects","volume":"15","author":"Vogelman","year":"1985","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041008422142600_b9-0721357","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/jac\/33.5.937","article-title":"Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro","volume":"33","author":"Karlowsky","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041008422142600_b10-0721357","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1592\/phco.19.16.1252.30876","article-title":"Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside","volume":"19","author":"Murry","year":"1999","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t2019041008422142600_b11-0721357","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2125.1995.tb05719.x","article-title":"A suggested approach to once-daily aminoglycoside dosing","volume":"39","author":"Begg","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041008422142600_b12-0721357","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1445-5994.1995.tb01529.x","article-title":"Experience of once-daily aminoglycoside dosing using a target area under the concentration\u2013time curve","volume":"25","author":"Barclay","year":"1995","journal-title":"Aust NZ J Med"},{"key":"key\n\t\t\t\t2019041008422142600_b13-0721357","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","article-title":"Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity","volume":"43","author":"Rybak","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041008422142600_b14-0721357","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1365-2710.1998.00174.x","article-title":"Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules","volume":"23","author":"Sanchez-Alcaraz","year":"1998","journal-title":"J Clin Pharm Ther"},{"key":"key\n\t\t\t\t2019041008422142600_b15-0721357","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/infdis\/159.5.931","article-title":"Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage","volume":"159","author":"Sturm","year":"1989","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019041008422142600_b16-0721357","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/jac\/23.5.773","article-title":"A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections","volume":"23","author":"Hollender","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041008422142600_b17-0721357","first-page":"531","article-title":"Easier monitoring of aminoglycoside therapy with once-daily dosing schedules","volume":"14","author":"Prins","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041008422142600_b18-0721357","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1128\/AAC.44.4.809-813.2000","article-title":"Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration","volume":"44","author":"Beringer","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041008422142600_b19-0721357","first-page":"2016","article-title":"Extended dosage intervals for aminoglycosides","volume":"51","author":"Rodman","year":"1994","journal-title":"Am J Hosp Pharm"},{"key":"key\n\t\t\t\t2019041008422142600_b20-0721357","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1177\/106002809402800614","article-title":"Once-daily administration of aminoglycosides","volume":"28","author":"Bates","year":"1994","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t2019041008422142600_b21-0721357","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/jac\/39.6.677","article-title":"Once-daily dosing of aminoglycosides: review and recommendations for clinical practice","volume":"39","author":"Freeman","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041008422142600_b22-0721357","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)70798-4","article-title":"Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis\u2014the TOPIC study: a randomised controlled trial","volume":"365","author":"Smyth","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041008422142600_b23-0721357","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/clinids\/24.5.786","article-title":"A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides","volume":"24","author":"Bailey","year":"1997","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041008422142600_b24-0721357","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/jac\/29.4.427","article-title":"Comparison of gentamicin dosing regimens using an in-vitro model","volume":"29","author":"Begg","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041008422142600_b25-0721357","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2,184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041008422142600_b26-0721357","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/clinids\/24.5.796","article-title":"A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides","volume":"24","author":"Ali","year":"1997","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041008422142600_b27-0721357","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF00202170","article-title":"Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety","volume":"48","author":"Galloe","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041008422142600_b28-0721357","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1592\/phco.30.1.95","article-title":"Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis","volume":"30","author":"Prescott","year":"2010","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t2019041008422142600_b29-0721357","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/bmj.312.7027.338","article-title":"Single or multiple daily doses of aminoglycosides: a meta-analysis","volume":"312","author":"Barza","year":"1996","journal-title":"Br J Med"},{"key":"key\n\t\t\t\t2019041008422142600_b30-0721357","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/clpt.1989.4","article-title":"Once-daily dosing decreases renal accumulation of gentamicin and netilmicin","volume":"45","author":"Verpooten","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2019041008422142600_b31-0721357","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1128\/AAC.40.11.2494","article-title":"Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy","volume":"40","author":"Prins","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041008422142600_b32-0721357","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003088-199936020-00001","article-title":"Once daily aminoglycoside therapy: is it less toxic than multiple daily doses and how should it be monitored?","volume":"36","author":"Barclay","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t2019041008422142600_b33-0721357","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/infdis\/167.1.173","article-title":"Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring","volume":"167","author":"Bertino","year":"1997","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019041008422142600_b34-0721357","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/jac\/24.3.281","article-title":"Determinants of efficacy and toxicity of aminoglycosides","volume":"24","author":"Mattie","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041008422142600_b35-0721357","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00003088-198713040-00002","article-title":"Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance","volume":"13","author":"De Groot","year":"1987","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t2019041008422142600_b36-0721357","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1128\/AAC.44.4.809-813.2000","article-title":"Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration","volume":"44","author":"Beringer","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041008422142600_b37-0721357","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)70798-4","article-title":"Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis\u2014the TOPIC study: a randomised controlled trial","volume":"365","author":"Smyth","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041008422142600_b38-0721357","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1183\/09031936.02.00221602","article-title":"Once-daily tobramycin in the treatment of adult patients with cystic fibrosis","volume":"19","author":"Whitehead","year":"2002","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t2019041008422142600_b39-0721357","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4212\/cjhp.v64i3.1020","article-title":"Extended-interval aminoglycoside therapy for adults with febrile neutropenia: a systematic review","volume":"64","author":"Stabler","year":"2011","journal-title":"Can J Hosp Pharm"},{"key":"key\n\t\t\t\t2019041008422142600_b40-0721357","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/jac\/31.4.585","article-title":"Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients","volume":"31","author":"Rozdzinski","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041008422142600_b41-0721357","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1445-5994.1998.tb01954.x","article-title":"Population analysis of once-daily dosing of gentamicin in patients with neutropenia","volume":"28","author":"Peterson","year":"1990","journal-title":"Aust N Z J Med"},{"key":"key\n\t\t\t\t2019041008422142600_b42-0721357","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00004630-199703000-00005","article-title":"Wide variation in single, daily dose aminoglycoside pharmacokinetics in patients with burn injuries","volume":"18","author":"Hoey","year":"1997","journal-title":"J Burn Care Rehabil"},{"key":"key\n\t\t\t\t2019041008422142600_b43-0721357","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/FTD.0b013e31818b6b2f","article-title":"Suboptimal aminoglycoside dosing in critically ill patients","volume":"30","author":"Rea","year":"2008","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t2019041008422142600_b44-0721357","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/00005373-200011000-00013","article-title":"Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens","volume":"49","author":"Barletta","year":"2000","journal-title":"J Trauma"},{"key":"key\n\t\t\t\t2019041008422142600_b45-0721357","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"key\n\t\t\t\t2019041008422142600_b46-0721357","first-page":"223","article-title":"Once-daily dosing of aminoglycosides: a consensus document","volume":"35","author":"Anaizi","year":"1997","journal-title":"Int J Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2019041008422142600_b47-0721357","article-title":"Aminoglycosides, overview [monograph]","volume-title":"Sanford Antimicrobial Guide [online database]"},{"key":"key\n\t\t\t\t2019041008422142600_b48-0721357","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1592\/phco.22.13.1077.33529","article-title":"Evaluation of four once-daily aminoglycoside dosing nomograms","volume":"22","author":"Wallace","year":"2002","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t2019041008422142600_b49-0721357","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1128\/AAC.41.5.1115","article-title":"Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing","volume":"41","author":"Demczar","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041008422142600_b50-0721357","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/jac\/38.5.885","article-title":"Development of guidelines for gentamicin dosing","volume":"38","author":"Thomson","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041008422142600_b51-0721357","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00007691-199606000-00007","article-title":"Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring","volume":"18","author":"Nicolau","year":"1996","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t2019041008422142600_b52-0721357","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/j.1875-9114.1997.tb03760.x","article-title":"Pharmacoeconomic impact of once-daily aminoglycoside administration","volume":"17","author":"Hitt","year":"1997","journal-title":"Pharmacotherapy"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/72\/16\/1357\/28320353\/ajhp1357.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T22:02:20Z","timestamp":1748556140000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/72\/16\/1357\/5111703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,15]]},"references-count":52,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2015,8,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp140564","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,8,15]]},"published":{"date-parts":[[2015,8,15]]}}}